High protein diet maintains glucose production during exercise-induced energy deficit: a controlled trial

<p>Abstract</p> <p>Background</p> <p>Inadequate energy intake induces changes in endogenous glucose production (GP) to preserve muscle mass. Whether addition provision of dietary protein modulates GP response to energy deficit is unclear. The objective was to determine whether exercise-induced energy deficit effects on glucose metabolism are mitigated by increased dietary protein.</p> <p>Methods</p> <p>Nineteen men ([mean ± SD] 23 ± 2 y, VO_2peak59 ± 5 ml·kg^-1·min^-1) were divided into three groups, two consuming moderate (MP; 0.9 g protein kg^-1d^-1), and one high (HP; 1.8 g protein kg^-1d^-1) protein diets (55% energy from carbohydrate) for 11 days. Following 4 days of energy balance (D1-4), energy expenditure was increased for 7 days (D5-12) in all groups. Energy intake was unchanged in two, creating a 1000 kcal d^-1deficit (DEF-MP, DEF-HP; n = 6, both groups), whereas energy balance was maintained in the third (BAL-MP, n = 7). Biochemical markers of substrate metabolism were measured during fasting rest on D4 and D12, as were GP and contribution of gluconeogenesis to endogenous glucose production (<it>f</it>_gng) using 4-h primed, continuous infusions of [6,6-²H₂]glucose (dilution-method) and [2-¹³C]glycerol (MIDA technique). Glycogen breakdown (GB) was derived from GP and <it>f</it>_gng.</p> <p>Results</p> <p>Plasma β-hydroxybutyrate levels increased, and plasma glucose and insulin declined from D4 to D12, regardless of group. DEF-MP experienced decreased plasma GP from D4 to D12 ([mean change ± SD] 0.24 ± 0.24 mg·kg^-1·min^-1), due to reduced GB from D4 (1.40 ± 0.28 mg·kg^-1·min^-1) to D12 (1.16 ± 0.17 mg·kg^-1·min^-1), P < 0.05. Conversely, BAL-MP and DEF-HP sustained GP from D4 to D12 ([mean change ± SD] 0.1 ± 0.5 and 0.0 ± 0.2 mg·kg^-1·min^-1, respectively) by maintaining GB.</p> <p>Conclusion</p> <p>Exercise-induced energy deficit decreased GP and additional dietary protein mitigated that effect.</p

An ethanolic extract of artemisia scoparia inhibits lipolysis in vivo and has antilipolytic effects on murine adipocytes in vitro

© 2018, American Physiological Society. All rights reserved. An ethanolic extract of Artemisia scoparia (SCO) has metabolically favorable effects on adipocyte development and function in vitro and in vivo. In diet-induced obese mice, SCO supplementation significantly reduced fasting glucose and insulin levels. Given the importance of adipocyte lipolysis in metabolic health, we hypothesized that SCO modulates lipolysis in vitro and in vivo. Free fatty acids and glycerol were measured in the sera of mice fed a high-fat diet with or without SCO supplementation. In cultured 3T3-L1 adipocytes, the effects of SCO on lipolysis were assessed by measuring glycerol and free fatty acid release. Microarray analysis, qPCR, and immunoblotting were used to assess gene expression and protein abundance. We found that SCO supplementation of a high-fat diet in mice substantially reduces circulating glycerol and free fatty acid levels, and we observed a cell-autonomous effect of SCO to significantly attenuate tumor necrosis factor-α (TNFα)-induced lipolysis in cultured adipocytes. Although several prolipolytic and antilipolytic genes were identified by microarray analysis of subcutaneous and visceral adipose tissue from SCO-fed mice, regulation of these genes did not consistently correlate with SCO’s ability to reduce lipolytic metabolites in sera or cell culture media. However, in the presence of TNFα in cultured adipocytes, SCO induced antilipolytic changes in phosphorylation of hormone-sensitive lipase and perilipin. Together, these data suggest that the antilipolytic effects of SCO on adipose tissue play a role in the ability of this botanical extract to improve whole body metabolic parameters and support its use as a dietary supplement to promote metabolic resiliency

Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice

Pathological studies on Parkinson’s disease (PD) patients suggest that PD pathology progresses from the enteric nervous system (ENS) and the olfactory bulb into the central nervous system. We have previously shown that environmental toxins acting locally on the ENS mimic this PD-like pathology progression pattern in mice. Here, we show for the first time that the resection of the autonomic nerves stops this progression. Moreover, our results show that an environmental toxin (i.e. rotenone) promotes the release of alpha-synuclein by enteric neurons and that released enteric alpha-synuclein is up-taken by presynaptic sympathetic neurites and retrogradely transported to the soma, where it accumulates. These results strongly suggest that pesticides can initiate the progression of PD pathology and that this progression is based on the transneuronal and retrograde axonal transport of alpha-synuclein. If confirmed in patients, this study would have crucial implications in the strategies used to prevent and treat PDThis work was supported by the Fritz-Thyssen Foundation, theGerman Parkinson’s disease Society and by Amelia Jimenez Gomez as private dono

An overview of DLR compound rotorcraft aerodynamics and aeroacoustics activities within the CleanSky2 NACOR Project

The challenge of increasing range and speed of a rotorcraft is encountered in the scope of the European CleanSky2 “Fast Rotorcraft” project by Airbus Helicopters with the compound helicopter design RACER (RapidAndCostEfficientRotorcraft) for which the box wing and the tail parts designs are respectively protected by patent. This paper presents the DLR contributions to the RACER development. This includes the aerodynamic design of the wing and tail section as well as an overall assessment of performance and noise. In a first step the aerodynamic properties of the configuration are evaluated both isolated and with consideration of the main rotor and lateral rotor interferences by the use of actuator discs. In the second step, the investigated possibilities to improve the configurations performance are described. These include airfoil design for improved high lift performance of the wing and tail section, an optimization of the box wing circulation distribution on the upper and lower wing. Additionally, the intersection fairings were improved and the efficiency of the trim flaps was evaluated. In this regard, it could be determined for which cases an isolated approach is appropriate and when the rotor interference should be considered. At the end the evaluation of the aero acoustics of the configuration is conducted. The applied configuration shows good aerodynamic characteristics with some further cruise and off design optimization potential

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

Improvement in Peripheral Glucose Uptake After Gastric Bypass Surgery Is Observed Only After Substantial Weight Loss Has Occurred and Correlates with the Magnitude of Weight Lost

# 2009 The Author(s). This article is published with open access at Springerlink.com Introduction Altered gut and pancreatic hormone secretion may bolster resolution of insulin resistance after Roux-en-Y gastric bypass (RYGB), but the independent effects of weight loss and hormonal secretion on peripheral glucose disposal are unknown. Methods Two groups of nondiabetic morbidly obese patients were studied: RYGB followed by standardized caloric restriction (RYGB, n=12) or caloric restriction alone (diet, n=10). Metabolic evaluations (euglycemic–hyperinsulinemic clamp, meal tolerance test) were done at baseline and 14 days (both groups) and 6 months after RYGB